Ivonescimab (SMT112)

Potential First-in-Class PD-1/VEGF Bispecific Antibody

Summit therapeutics

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
It is currently being investigated in Phase III clinical studies.

IVONESCIMAB (SMT112)

PD-1/VEGF Bispecific Antibody

Ivonescimab, known as AK112 in China and non-Summit territories, and also as SMT112 in the United States, Canada, Europe, and Japan (Summit License Territories), is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking of VEGF into a single molecule. Ivonescimab is the most advanced PD-1/VEGF bispecific antibody in clinical development in the Summit License Territories: there are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration ("FDA") or the European Medicines Agency ("EMA").

Summit is initiating development activities for SMT112 first in NSCLC indications. Summit plans to start treating patients in clinical studies by the second quarter of 2023.

SMT112
United States, Canada,
Europe, Japan
(Summit License Territories)

AK112
China &
Non-Summit Territories

Summit therapeutics

IVONESCIMAB (SMT112)

PD-1/VEGF Bispecific Antibody

Ivonescimab was engineered to bring two well established oncology targeted therapies together.

IVONESCIMAB (SMT112)

PD-1/VEGF Bispecific Antibody



Ivonescimab Has Received Breakthrough Therapy Designation Status in China[1]

from the National Medical Products Administration (NMPA) for three indications: combination therapy with chemotherapy for non-small cell lung cancer (NSCLC) patients who have failed a previous epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI), combination therapy with chemotherapy for NSCLC patients who have failed to respond to a prior PD-(L)1 therapy, and monotherapy as first-line treatment for locally advanced or metastatic NSCLC patients with positive PD-(L)1 expression. Ivonescimab is currently being developed in China and Australia in multiple solid tumors, including a Phase III clinical trial in patients with NSCLC that are positive for an EGFR mutation whose disease has progressed after treatment with an EGFR-TKI.

1. Akeso. November 13, 2022. Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China. [Press Release]. https://www.akesobio.com/en/media/akeso-news/20221113.

Contact: medicalinformation@smmttx.com

Summit Therapeutics, Inc. offices are located in Menlo Park, CA; Oxford, UK; Cambridge, UK
smmttx.com